Open AccessA Review on Pharmacological and Therapeutical Insight of Satranidazole for Colon Targeting in the treatment of Colonic Diseases
Author(s) -
Soumyadip Ghosh,
Debgopal Ganguly,
Subhabrota Majumder,
Ananta Chowdhury
Publication year - 2022
Publication title -
journal of drug delivery and therapeutics
Language(s) - English
Resource type - Journals
ISSN - 2250-1177
DOI - 10.22270/jddt.v12i1-s.5348
Subject(s) - medicine , ulcerative colitis , adverse effect , drug , inflammatory bowel disease , metronidazole , disease , colitis , targeted drug delivery , antibiotics , pharmacology , microbiology and biotechnology , biology
Drugs targeting the colonic environment to treat various colonic diseases are the major challenges recently. Various drugs are available in the markets to targeting to the colonic region to treat diseases but due to premature drug releases, target specificity, the low concentration at the target site with high adverse effects which increase patients’ compliance day by day. Satranidazole is a promising drug that is particularly targeting the colonic environment and can break down microorganism DNA to involve the treatment of several diseases such as inflammatory bowel diseases subdivided Ulcerative colitis, Crohn’s disease, amoebiasis, chronic diarrhea, and reduction of pain due to inflammation. Conventional drug delivery of Satranidazole has some disadvantages such as target specificity, high dosing frequency, low therapeutic efficacy, and high adverse effects that can be overcome through targeted drug delivery systems. Satranidazole is successfully showing the efficacy against aerobic, microaerophilic as well as anaerobic bacterial and reduction of inflammation of inflammatory bowel diseases subdivided as Ulcerative colitis and Crohn’s disease. It is a much more potent drug than metronidazole and has fewer adverse effects. Satranidazole is more convenient for oral administration compared to other routes of administration to show activity. Researchers are giving much more attention to targeted drug delivery systems of Satranidazole to show high therapeutic activity with fewer side effects. The current review focus on the pharmacological and therapeutical insight of Satranidazole in the treatment of colonic diseases and recent advancement and the future aspects of Satranidazole targeting various diseases.
Keywords: Satranidazole, Inflammatory bowel diseases, Ulcerative colitis, Crohn’s disease, Amoebiasis, Targeted drug delivery system, Future advancement, Colonic drug delivery systems.